IP Library › Granted Patent US 11,719,698
Granted Patent B2
US 11,719,698 · App. 15/103,264 · Granted Aug 8, 2023

Cancer detection method using sense of smell of nematode

Inventors: Takaaki Hirotsu (Fukuoka, JP); Hideto Sonoda (Saga, JP)
Assignee: HIROTSU BIO SCIENCE INC.
G01N33/57488C12Q1/6888C12Q2600/112C12Q2600/158G01N2333/43534
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,719,698
App. No.
15/103,264
Granted
Aug 8, 2023
Kind
B2
Abstract

A cancer detection method characterised in that a nematode is bred in the presence of bio-related material originating from a test subject, or a processed product of same, and cancer is detected using the chemotaxis due to the sense of smell of the nematode as an indicator.

Claims (20)

1. A method for detecting cancer in a subject, comprising the steps of:

(a) obtaining a test sample which comprises urine, a cell culture medium, or a preservative solution of the cells or tissues from the subject and wherein a concentration of the urine, the cell culture medium, or the preservative solution of the cells or tissues is diluted with a diluting liquid,

wherein the urine is diluted to 1.5 to 1000 times or the cell culture medium is diluted to 10 6 to 10 7 times, or the preservative solution of the cells or preservative solution of the tissues is diluted to 10 2 to 10 4 times;

(b) exposing Caenorhabditis elegans nematodes to the test sample and a control sample separately, and

(c) assaying a chemotaxis of the Caenorhabditis elegans nematodes to the test sample and the control sample separately,

wherein a positive chemotaxis by the Caenorhabditis elegans nematodes to the test sample indicates that the subject is determined to have cancer, or to have a risk of having cancer, and

wherein a negative chemotaxis by the Caenorhabditis elegans nematodes to the test sample indicates that the subject is not determined to have cancer, or have the risk of having cancer.

2. The method according to claim 1 , wherein the Caenorhabditis elegans nematodes are wild-type nematodes, mutant nematodes or transgenic nematodes, wherein the mutant nematodes or transgenic nematodes retain the ability to exhibit chemotaxis to the test sample.

3. The method according to claim 1 , wherein the test sample is urine.

4. A method for identifying at least one olfactory receptor in Caenorhabditis elegans nematodes, comprising the steps of:

(a) obtaining a test sample which comprises urine, a cell culture medium, or a preservative solution of the cells or tissues from the subject and wherein a concentration of the urine is diluted to 1.5 to 1000 with a diluting liquid, or the cell culture medium is diluted to 10 6 to 10 7 with a diluting liquid, or the preservative solution of the cells or preservative solution of the tissues is diluted to 10 2 to 10 4 with a diluting liquid;

(b) modifying at least one gene or a part of the at least one gene encoding the at least one olfactory receptor in Caenorhabditis elegans nematodes;

(c) testing a chemotaxis of the modified Caenorhabditis elegans nematodes to the test sample;

wherein a defect in the chemotaxis in comparison to a chemotaxis of control Caenorhabditis elegans nematodes indicates that the at least one olfactory receptor is associated with an odorant in a smell of the urine, cells, tissues, cell culture medium, or preservative solution.

5. The method according to claim 4 , wherein the modifying at least one gene or part of the at least one gene in step (b) comprises inhibiting the expression or function of said gene or part of said gene by RNAi.

6. The method according to claim 4 , wherein the type of a receptor identified is different depending on cancer types or the concentration of the odorant.

7. The method according to claim 4 , wherein the subject is a cancer patient.

8. The method according to claim 1 , wherein the diluting fluid is water or a buffer.

9. The method according to claim 1 , wherein the control sample is a diluted control sample from a healthy subject or a cancer patient.

10. The method according to claim 1 , wherein the control sample comprises at least one odorant selected from the group consisting of isoamyl alcohol, benzaldehyde, butanone, pentanedione, pyrazine, trimethylthiazole, nonanone, octanol, and diacetyl.

Assignments (3)
CHANGE OF ADDRESS Recorded Mar 10, 2023
From: HIROTSU BIO SCIENCE INC.
To: HIROTSU BIO SCIENCE INC.
Reel/Frame 063026/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2019
From: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
To: HIROTSU BIO SCIENCE INC.
Reel/Frame 049423/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2016
From: HIROTSU, TAKAAKI; SONODA, HIDETO
To: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
Reel/Frame 038880/0041 →
Priority Claims (1)
JP 2013-255145 · Dec 10, 2013 · national
Continuity (2)
Provisional Application 61982341 · Apr 22, 2014
Related Publication 20170016906A1 · Jan 19, 2017